# A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06372865 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)

> **NCT02070289** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 50 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** PF-06372865
- **DRUG:** Placebo
- **DRUG:** PF-06372865
- **DRUG:** Placebo
- **DRUG:** PF-06372865
- **DRUG:** Placebo
- **DRUG:** PF-06372865
- **DRUG:** Placebo
- **DRUG:** PF-06372865
- **DRUG:** Placebo
- **DRUG:** PF-06372865

## Key facts

- **NCT ID:** NCT02070289
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2014-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02070289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02070289, "A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06372865 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02070289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*